ZOLL Announces Approval of Next-Generation remedē System for the Treatment of Central Sleep Apnea (transvenous phrenic nerve stimulation)
The new remedē EL-X model delivers extended longevity, reduced size, and an enhanced suite of diagnostics
August 5, 2021
The new remedē EL-X model delivers extended longevity, reduced size, and an enhanced suite of diagnostics
July 10, 2019
Respicardia Also Initiates 500-Patient Prospective, Global, Single-Arm Longitudinal Study
October 20, 2020
Trial results showed consistent improvement in sleep disordered breathing, arousals, sleep architecture, and daytime sleepiness through 5 years.
January 6, 2020
The first general hospital in Texas to treat a patient with the remedē® System
June 1, 2020
Respicardia, Inc. announced today that Richard L. Roudebush VA Medical Center in Indianapolis is the first center in Indiana to treat patients with the remedē® System, an implantable device that uses phrenic nerve stimulation to treat central sleep apnea (CSA).